RC
ARRY

RegentAtlantic Capital’s Array Biopharma Inc ARRY Stock Holding History

RegentAtlantic Capital’s Portfolio ARRY Stock Details ARRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-1,000
Closed -$4.73K – 1081
2014
Q4 		$4.73K Buy
+1,000
New +$3.96K ﹤0.01% 1019

Other funds holding ARRY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RegentAtlantic Capital's ARRY Position: Q1 2015 in Review

RegentAtlantic Capital sold out of Array Biopharma Inc (ARRY) in Q1 2015, closing a stake of 1,000 shares — an estimated $4.73K sold.

RegentAtlantic Capital first reported a position in ARRY in Q4 2014 and held it in 1 quarter. The position peaked at $4.73K in Q4 2014. 133 funds tracked by Wall St. Rank hold ARRY as of Q1 2015.

  • RegentAtlantic Capital reported no remaining Array Biopharma Inc position as of Q1 2015 after selling out during the quarter.
  • RegentAtlantic Capital sold 1,000 Array Biopharma Inc shares in Q1 2015, an estimated $4.73K.
  • RegentAtlantic Capital first reported a position in Array Biopharma Inc in Q4 2014 and held it in 1 quarter.
  • RegentAtlantic Capital's Array Biopharma Inc position peaked at $4.73K in Q4 2014.
  • 133 funds tracked by Wall St. Rank held Array Biopharma Inc as of Q1 2015.

Based on RegentAtlantic Capital's 13F filing for Q1 2015, filed 27 Apr 2015.